Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,092 shares of the biopharmaceutical company’s stock after buying an additional 312 shares during the period. Stanley Laman Group Ltd.’s holdings in Bristol-Myers Squibb were worth $313,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. OFI Invest Asset Management acquired a new position in shares of Bristol-Myers Squibb during the third quarter valued at $25,000. Milestone Investment Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the third quarter valued at approximately $27,000. Blue Bell Private Wealth Management LLC increased its stake in shares of Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 200 shares during the period. Legacy Financial Group LLC bought a new stake in Bristol-Myers Squibb during the third quarter worth approximately $39,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth approximately $40,000. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research reports. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Up 0.4 %

BMY traded up $0.16 on Friday, reaching $44.86. 21,279,666 shares of the company traded hands, compared to its average volume of 15,968,238. Bristol-Myers Squibb has a 52-week low of $44.34 and a 52-week high of $69.10. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The company has a market cap of $90.92 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 1.47 and a beta of 0.39. The stock’s 50 day moving average price is $51.03 and its 200-day moving average price is $51.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. During the same period in the previous year, the company posted $2.05 EPS. Bristol-Myers Squibb’s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.35%. Bristol-Myers Squibb’s dividend payout ratio is 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.